Compare Mesoblast Limited (MESO) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VF Corp — how do they compare? Mesoblast Limited trades at $16.25 (market cap $2.17B), while VF Corp trades at $16.62 (market cap $6.62B). The key difference: VF Corp is far larger — about 3.1× Mesoblast Limited's market cap, and VF Corp pays a 2.13% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | VFC | |
|---|---|---|
Market Cap | $2.17B | $6.62B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $21.55 |
52-Week Low | $12.88 | $11.66 |
Enterprise Value | $2.17B | $10.77B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VFC trades at $16.78, down 1.18% on the day, with technical indicators showing a neutral to bearish short-term bias. The company reported mixed quarterly results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, with revenue declining to $9.50 billion in 2025. Analyst sentiment is cautiously optimistic with a consensus price target of $19.33, while recent news highlights ongoing brand challenges and debt reduction efforts.
The outlook for VFC hinges on execution of its turnaround strategy, particularly revitalizing the Vans brand. Near-term catalysts include Q2 2026 earnings and continued debt management, but risks remain from weak consumer spending and competitive pressures. The stock offers potential upside to analyst targets if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
